

1 **Title: Combined near infrared photoacoustic imaging and ultrasound detects vulnerable**
2 **atherosclerotic plaque**

3 Martin Karl Schneider^{1*}, James Wang^{1*}, Aris Kare¹, Shaunak S. Adkar², Darren Salmi³, Caitlin F. Bell²,
4 Tom Alsaigh², Dhananjay Wagh⁴, John Collier⁴, Aaron Mayer⁵, Sarah J. Snyder⁶, Alexander D.
5 Borowsky⁷, Steven R. Long⁸, Maarten G. Lansberg⁹, Gary K. Steinberg¹⁰, Jeremy J. Heit⁶, Nicholas J.
6 Leeper², Katherine W. Ferrara¹

7 *authors contributed equally

8
9 ¹ Molecular Imaging Program at Stanford and Bio-X Program, Department of Radiology, Stanford
10 University School of Medicine, Palo Alto, CA 94305, USA

11 ² Department of Surgery, Division of Vascular Surgery, Stanford University School of Medicine,
12 Stanford, CA 94305, USA.

13 ³ Department of Pathology, Stanford University School of Medicine, Palo Alto, CA 94305, USA

14 ⁴ Sequencing Group Stanford Genomics, Stanford University School of Medicine, Palo Alto, CA 94305,
15 USA

16 ⁵ Enable Medicine, Menlo Park, CA, 94025, USA

17 ⁶ Department of Radiology and Neurosurgery, Stanford University School of Medicine, Palo Alto, CA
18 94305, USA

19 ⁷ Department of Pathology and Laboratory Medicine, UC Davis School of Medicine, Davis, CA 95616,
20 USA

21 ⁷ Department of Neurosurgery, Stanford University School of Medicine, Palo Alto, CA 94305, USA

22 ⁸ Department of Pathology, University of California San Francisco, San Francisco, CA 94110, USA

23 ¹⁰ Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo
24 Alto, CA 94305, USA

25
26
27
28 **Keywords:**

29 Photoacoustic imaging, spatial transcriptomics, atherosclerosis, vulnerable plaque, NIR biomarker

30
31 **Abstract**

32 Atherosclerosis is an inflammatory process resulting in the deposition of cholesterol and cellular debris,
33 narrowing of the vessel lumen and clot formation. Characterization of the morphology and vulnerability
34 of the lesion is essential for effective clinical management. Photoacoustic imaging has sufficient
35 penetration and sensitivity to map and characterize human atherosclerotic plaque. Here, near infrared
36 photoacoustic imaging is shown to detect plaque components and, when combined with ultrasound
37 imaging, to differentiate stable and vulnerable plaque. In an *ex vivo* study of photoacoustic imaging of
38 excised plaque from 25 patients, 88.2% sensitivity and 71.4% specificity were achieved using a clinically-
39 relevant protocol. In order to determine the origin of the near-infrared auto-photoacoustic (NIRAPA) signal,
40 immunohistochemistry, spatial transcriptomics and proteomics were applied to adjacent sections of the
41 plaque. The highest NIRAPA signal was spatially correlated with bilirubin and associated blood-based
42 residue and inflammatory macrophages bearing CD74, HLA-DR, CD14 and CD163 markers. In summary,
43 we establish the potential to apply the NIRAPA-ultrasound imaging combination to detect vulnerable
44 carotid plaque.

46 INTRODUCTION

47 Cardiovascular diseases, which include coronary heart disease, peripheral arterial disease and stroke,
48 are the leading cause of death globally^{1, 2}. In the United States, heart disease was the first and stroke
49 the fifth leading cause of death in 2020³. The cause of these diseases in most cases is atherosclerosis¹.
50 Atherosclerosis is an inflammatory process resulting in the deposition of fatty and/or necrotic residues in
51 the vessel wall and consequently the narrowing of the vessel lumen. The rupture of an atherosclerotic
52 plaque and the following formation of a thrombus in the blood circulation can result in ischemic events
53 such as myocardial infarction or stroke^{1, 4, 5}. Silent, asymptomatic atherosclerosis is a common finding in
54 the general population, even in young adults, and is typically associated with a low risk of myocardial
55 infarction or stroke⁶⁻⁸; however, more than half of the acute coronary syndrome cases originate from
56 these clinically silent plaques⁹⁻¹¹. For that reason, it is critical to understand the phenotypic characteristics
57 of plaques, which can help develop imaging solutions for early detection^{12, 13}.

58
59 For the characterization of plaque types, specific histomorphological markers have been identified,
60 including percent luminal stenosis, fibrous cap thickness, macrophage area, necrotic core area and
61 calcified plaque area^{14, 15}. The fibrous cap of an atherosclerotic plaque is one of the best discriminators
62 of stable versus unstable plaque type^{5, 14, 16, 17}. Standard imaging techniques to detect carotid
63 atherosclerotic plaques are Doppler ultrasound, magnetic resonance (MR) angiography and computed
64 tomography (CT) angiography. The clinical treatment process, including decisions about when to offer
65 prophylactic surgery, is primarily based on the extent of luminal stenosis¹⁸. Novel imaging methods,
66 including high-resolution MRI, CT combined with positron emission tomography (PET) imaging, and
67 photoacoustic imaging are being tested to better assess the vessel wall features of the plaque in order
68 to determine the plaques vulnerability¹⁸⁻²⁰. Photoacoustic imaging utilizes laser light in the near-infrared
69 range (680–980 nm) to excite endogenous or exogenous chromophores in the tissue in order to generate
70 an ultrasound wave that can be combined with regular ultrasound scans²¹. Of particular clinical interest
71 are endogenous chromophores used to acquire molecular tissue information without the requirement for
72 an exogenous contrast agent. Specific endogenous tissue components including oxyhemoglobin (HbO₂),
73 deoxyhemoglobin (Hb), H₂O, melanin and lipids can be identified via photoacoustic imaging based on
74 their characteristic absorption spectra^{22, 23}. Previous attempts to detect vulnerable plaque features via
75 photoacoustic imaging focused on lipids (950-1250 nm)²⁴⁻²⁶ and intraplaque hemorrhage (808 nm)^{27, 28}.
76 Recently, bilirubin and other heme degradation products and insoluble lipid in atherosclerotic plaques
77 have been evaluated as to their autofluorescence properties in the near-infrared (680 nm) range²⁹. The
78 hemoglobin degradation products represent a pathological process indicative of intraplaque hemorrhage
79 and therefore serve as an important biomarker for vulnerable plaque²⁹⁻³¹. However, near-infrared
80 autofluorescence (NIRAF) in the 650-700 nm range suffers from limited penetration depth and spatial
81 resolution; and therefore, photoacoustic techniques are attractive^{22, 32}.

82
83 In this study, we investigate whether plaque components associated with the NIRAF signal can be
84 detected with a clinical photoacoustic device to reveal the characteristics of a vulnerable plaque, such as
85 thickness of a fibrous cap, infiltrating macrophages and necrotic core size. Further, we set out to
86 characterize the molecular characteristics of the components that were responsible for the signal. To
87 accomplish this, spatially registered near-infrared auto-photoacoustic (NIRAPA) and fluorescence
88 microscopy are combined with immunohistochemistry, spatial RNA sequencing and immunofluorescence
89 imaging via co-detection by indexing (CODEX)³³. Single-cell RNA sequencing has previously been
90 successfully applied in atherosclerosis to profile individual cells and has revealed valuable information
91 regarding infiltrating immune cells^{34, 35}; herein, we use spatial transcriptomics to associate NIRAF and
92 photoacoustic signal with the gene expression profile. Spatial transcriptomics was performed with a depth
93 of 15000 ~ 18000 genes at each location, thus enabling correlation of the NIRAF signal with specific
94 transcriptomic profiles³⁶. Protein immunofluorescence, with single-cell resolution and markers spanning
95 the NIRAF signal, immune and epithelial markers, was then applied to visualize the NIRAF signal
96 generated by individual immune cells and extracellular components. The combination of these techniques
97 (Extended Fig. 1) provides multiple levels of insight as to: 1) the association of the tissue level
98 photoacoustic signal with clinically-significant features, 2) the characterization of an inflammatory gene

99 signature that is primarily associated with the signal, and 3) confirmation that the photoacoustic and
100 NIRAF signals result from extracellular matrix components and CD74⁺ HLA-DR⁺ CD14⁺ macrophages.
101
102

103 MATERIALS AND METHODS

104 Human Carotid Endarterectomy Specimens

105 All human studies have been approved by the institutional review board at Stanford (IRB50541). To test
106 the ability of spectroscopic photoacoustic (sPA) imaging to guide treatment decisions, human carotid
107 plaques were used. Human carotid plaques were collected from 25 patients who presented to Stanford
108 Hospital, Palo Alto, US with clinical indications for Carotid Endarterectomy (CEA), where 24 samples
109 included carotid pathology and one sample was normal. In a subset of cases, contrast CT imaging and/or
110 color flow imaging studies were available based on standard of care parameters and these studies were
111 obtained and compared to the results. In each case, a region was scanned above and below the stenosis,
112 such that each study contained a control region. Imaging was performed over a 15 to 39 mm distance at
113 an inter-image distance of 0.2 mm, and the histology was acquired at an axial intersample distance of
114 1.5 cm. After surgical resection, the carotid specimens were immediately fixed in 4% paraformaldehyde
115 (PFA) for subsequent photoacoustic imaging (PAI) and histopathologic assessment, or were imaged with
116 PAI and fixed afterwards in 4% PFA. To evaluate the potential influence of PFA fixation on the PAI signal,
117 these specimens were imaged again after fixation. A preliminary study confirmed that the NIRAPA signal
118 was not impacted by fixation. sPA images and near-infrared auto-fluorescence (NIRAF) images were
119 analyzed and compared with the results of the histopathologic analysis.
120

121 Auto-near infrared photoacoustic imaging

122 Spectral photoacoustic images of the human carotid plaque were acquired using the Vevo LAZR-X
123 (FUJIFILM VisualSonics) with a 15 MHz linear array transducer (MX 201; axial resolution, 100 μ m) and
124 an average 150 mJ/cm² average fluence laser pulse (10 ns pulse width, 20 Hz pulse repetition frequency,
125 which has been optimized and calibrated). Single-plane, multiwavelength (680, 690, 700, 710, 720, 750,
126 800, 850 and 900 nm) photoacoustic images (Supplementary Fig.1) were acquired every 200 μ m based
127 on translation of a 3D stepper motor. B-mode ultrasound images were recorded simultaneously to provide
128 anatomic registration. An example of the NIRAPA images acquired to generate the spectrum
129 (Supplementary Fig. 1A) is provided as well as the estimated spectrum (labeled NIR-auto) for the plaque
130 region (Supplementary Fig. 1B). The spectral amplitude of the NIRAPA signal (Supplementary Fig. 1B)
131 is greatest in the lower NIR range (680-700 nm) and linearly decreases towards 950 nm. Spectral
132 unmixing of the signal was computed using the oxygenated (OXY) and deoxygenated (DeOXY)
133 hemoglobin settings on the Visualsonics yielding the estimated spectra and images (Supplementary Fig.
134 1B-D). Based on previous work demonstrating NIRAF from bilirubin²⁹, the bilirubin (B4126, Sigma-Aldrich)
135 absorption spectrum was first measured using a VisualSonics phantom, where the intensity decreases
136 with increasing wavelength and increases with bilirubin concentration (Supplementary Fig. 1C).
137

138 Matching photoacoustic imaging (PAI) images to histologic sections

139 Samples were with the Vevo LAZR-X (FUJIFILM VisualSonics) for NIRAPA signal. To evaluate the
140 clinical significance of the acquired PAI images, the corresponding histologic sections were examined in
141 a blinded manner by a board-certified pathologist, and the images were examined by two experts in the
142 field. The absence or thickness of the fibrous cap was recorded. Plaques with a fibrous plaque <65 μ m
143 or missing were classified as vulnerable plaques and plaques with a fibrous plaque >65 μ m were
144 determined as stable plaques³⁷. The PAI reviewer assessed the fibrous cap using PAI images overlaid
145 on top of B-mode ultrasound images. In each image, the NIRAPA signal was considered to be positive if
146 the area was greater than 2.5 mm². All cases included both positive images in the plaque center and
147 negative imaging at the axial extrema of the excised vessel. A positive image separated from the vessel
148 lumen by a hyperechoic ultrasound structure thicker than 65 μ m was termed as stable plaque. A positive
149 image adjacent to the vessel lumen with a smaller fibrous cap was assessed as vulnerable plaque.
150 Afterwards, the results and clinical symptoms were matched. For each patient, a proximal and distal
151 vascular region was identified and imaged to serve as an in-patient control. For the analysis of the PAI,

152 all images were reviewed for each case and the minimum fibrous cap distance was quantified along with
153 the maximum plaque volume.

154

155 **Spatial transcriptomic data processing**

156 Five- μm sections from tissue blocks were placed on the Visium slides and subjected to spatial analysis
157 using 10x Visium FFPE workflow (spatial resolution of 100 μm and with 1-10 cells per spot) (10x
158 Genomics, Pleasanton, CA). Manufacturer's instructions were followed without any significant alterations.
159 Individually indexed libraries were pooled and sequenced on NovaSeq 6000 (Illumina inc., San Diego,
160 CA) with the recommended read depth of per cell. Raw sequencing data was parsed through
161 SpaceRanger analysis platform (10x Genomics), aligned with human (GRCh38) reference and low
162 unique molecular identifier (UMI) counts were filtered. Transcriptomic analysis was performed with a
163 Seurat framework³⁸. Separate samples were merged and then normalized with the SCTransform
164 function, resulting in 3000-5000 spots for downstream processing. Principal component analysis was
165 performed and, based on the elbow plot, the first 75 principal components were selected for downstream
166 analysis. A resolution value of 0.4, k-nearest neighbors of 20, and the cutoff for Jaccard index of 0.005
167 were selected for Uniform Manifold Approximation and Projection (UMAP) clustering using the Leiden
168 algorithm. To investigate cluster cell type, spatially variable features and cluster distinctive markers were
169 determined with the FindSpatiallyVariableFeatures and FindAllMarkers function in the Seurat package
170³⁸. The top differentially expressed genes of each clusters were compared to key gene markers from the
171 literature to annotate clusters. The top differentially expressed genes from each sub-cluster were found
172 with the FindAllMarkers function. All transcriptomic data processing, analysis and visualization was done
173 with R language (version 4.2.2) in RStudio (RStudio team, PBC, Boston).

174

175 **CODEX processing**

176 Plaque histology formalin-fixed paraffin embedded (FFPE) slices were stained with 51-multiplexed
177 antibodies (Supplementary Table 4) and 3 spectral channels were co-acquired. After imaging processing,
178 cell segmentation was performed with the DeepCell algorithm through the EnableMedicine portal
179 (<https://app.enablemedicine.com/portal>). We further filtered the segmentation results based on size of
180 the cell, total biomarker intensity, DNA channel intensity and signal coefficient of variation. The filtered
181 segmentation results were then normalized and scaled for principal component analysis. UMAP
182 clustering based on the Leiden algorithm was performed on 25 principal components with the number of
183 k nearest neighbors, spread and minimum distance of clusters optimized to create a minimal number of
184 clusters. To explore co-expressions of key immune markers (CD163, CD68, CD14, HLA-DR), we subset
185 segmented cells with a normalized expression of larger than 2 and plotted a Venn diagram to visualize
186 the population distribution of cells with various co-expression combinations. To explore co-expression
187 signal level of key immune cell markers and NIRAF signal intensity, we computed the Pearson's
188 coefficient based on image signal intensity across the plaque for NIRAF signal intensity and the
189 fluorescence signal intensity of immune cell markers such as CD14, HLA-DR, CD163, and Collagen IV
190 as a negative control. Segmented cells were also exported to the cloud-based cytometry platform OMIQ
191 (<https://www.omiq.ai/>) for additional visualization of marker fluorescence signal intensity.

192

193 **Statistics**

194 Pearson correlation coefficients (r values) with estimated standard errors were used to determine
195 associations between NIRAF signal and histologic measurements of CD68 and bilirubin. ImageJ – JACoP
196 were used to calculate the Pearson correlation. An unpaired t test was used to evaluate the difference
197 between the unstable plaque area NIRAPA signal and the stable plaque area NIRAPA signal. Simple
198 linear regression was performed, and all graphs were created using GraphPad Prism version 9.3.1 for
199 Windows (GraphPad Software, San Diego, California USA, www.graphpad.com). Sensitivity, specificity,
200 positive predictive value and negative predictive value of PAI were determined with histologic analysis
201 used as the reference standard.

202

203 RESULTS

204 205 NIRAF / NIRAPA signal correlates with macrophages and bilirubin

206
207 To assess the feasibility of using spectroscopic photoacoustic (sPA) imaging for the detection of
208 vulnerable atherosclerotic plaques, 24 diseased human carotid plaques and one pathologically normal
209 artery were collected from patients who underwent carotid endarterectomy (CEA) at Stanford Hospital,
210 Palo Alto, USA. Twelve carotid plaques were collected from patients presenting with symptoms such as
211 stroke or transient ischemic attacks, and 12 CEA samples were classified as asymptomatic (Fig. 1). The
212 excised carotid (Fig. 1A-B) was subjected to NIRAPA imaging (Fig. 1C), where the images were oriented
213 using CT (Fig. 1D) and color flow ultrasound (Fig. 1E) imaging. Most importantly, the NIRAPA images
214 provide a positive contrast image of the plaque, as compared with the negative contrast produced by the
215 absence of blood flow in CT and color flow ultrasound imaging. In all 24 diseased cases, the NIRAPA
216 signal was detected in all patients in multiple imaging planes with the imaged region of interest spanning
217 15 to 40 mm (Fig. 1F).

218
219 A further example of the correspondence of the NIRAPA imaging and *in vivo* CT imaging, each acquired
220 along the longitudinal axis, is provided in Supplementary Fig. 2. This clinical CT scan cannot distinguish
221 between stable and unstable plaque components, whereas the photoacoustic scan can detect the
222 NIRAPA signal and discriminate these different features. As a result, photoacoustic scanning is valuable
223 for imaging the location of the stenosis and has clinical advantages when combined with other imaging
224 modalities.

225
226 The acquired PAI cross-sectional images and corresponding histological sections and stains, spanning
227 H&E, Masson's trichrome, picrosirius red, CD68, and bilirubin (Fig. 1F), were registered to the acquired
228 NIRAF image from the same slide, with the NIRAF signal representing the NIRAPA signal. A clear spatial
229 correlation was observed between the NIRAPA and NIRAF signals, CD68, and bilirubin (Fig. 1F);
230 therefore, we sought to quantify the correlation across the entire population in additional studies.
231 Masson's trichrome further defined regions of connective tissue and picrosirius red defined the collagen-
232 rich regions.

233 234 NIRAPA signal distinguishes between stable and unstable plaque

235 In order to evaluate the accuracy of photoacoustic images regarding discriminating stable plaque regions
236 (a fibrous cap rich in collagen and alpha smooth muscle actin) versus unstable (vulnerable) plaque
237 regions, the NIRAPA signal in the 680-700 nm range was compared to corresponding picrosirius red
238 histological sections, indicating collagen-rich regions (Fig. 2). To evaluate the fibrous cap thickness, the
239 distance between vessel lumen and unstable plaque region was measured using a cross-sectional
240 ultrasound image overlaid with the NIRAPA signal of the carotid plaque. In the picrosirius red stain, the
241 respective fibrous cap thickness was determined by measuring the distance between vessel lumen and
242 signal-free areas within the vessel wall. If the fibrous cap was absent or undetected, we measured
243 adjacent connective tissue areas and compared them to picrosirius red stain measurements. The
244 measured fibrous cap thickness within the ultrasound-NIRAPA images correlated with the measured
245 values from the picrosirius red histological images ($r^2 = 0.9913$) (Fig. 2A). The same cross-section images
246 were then used to evaluate the necrotic core area and the NIRAPA signal intensity difference between
247 stable and unstable regions. The measured necrotic core areas based on NIRAPA signal corresponded
248 to the signal-free picrosirius red stain areas ($r^2 = 0.8612$) (Fig. 2B). Accordingly, the NIRAPA signal
249 intensity recorded in unstable plaque areas was significantly higher than in stable plaque areas ($p < 0.0001$,
250 Fig. 2C).

251
252
253
254
255

256 **NIRAPA plus ultrasound: sensitivity and specificity**

257

258 The histological sections and NIRAPA-ultrasound images were then classified as stable or
259 unstable/vulnerable, based on a fibrous cap thickness greater or less than 65 μm , respectively (Fig. 2D)³⁹.
260 In this comparison, NIRAPA images (using histology as a gold standard) achieved 88.2% sensitivity and
261 71.4% specificity (88.2% positive predictive value, 71.4% negative predictive value). In order to evaluate
262 the clinical importance of NIRAPA images, we looked at asymptomatic cases separately. In 12
263 asymptomatic plaques, photoacoustic imaging reached 87.5% sensitivity and 100% specificity (100%
264 positive predictive value, 80% negative predictive value) (Fig. 2E).

265

266 **Correlation of the NIRAPA signal with macrophages and bilirubin**

267

268 We then sought to determine the origin of the NIRAPA signal. The naturally-occurring near-infrared signal
269 correlated with the CD68 macrophage marker (Pearson's coefficient 0.4, $p < 0.0001$) and bilirubin
270 (Pearson's coefficient 0.4, $p < 0.0001$), a degradation product of hemoglobin, in comparison with alpha
271 smooth muscle actin (αSMA), a marker for a healthy and stable artery (Fig. 3A-B). Correspondingly, in
272 the absence of a NIRAF signal, the detected area of CD68 and bilirubin ($p < 0.0001$) was negligible and
273 significantly lower than the αSMA area (Fig. 3A, C). This correlation with both macrophage localization
274 and bilirubin concentration motivated us to further evaluate the molecular basis of the signal using spatial
275 transcriptomics and proteomics.

276

277 **Spatial transcriptomics and proteomic mapping in stable plaque**

278

279 Imaging, immunohistochemistry (IHC), and spatial transcriptomic sequencing were performed on the
280 plaque slide sections to probe the genetic character with respect to spatial location. As noted earlier,
281 NIRAPA imaging corresponded closely with CT imaging and the location of the lesion (Supplementary
282 Fig. 2). Based on the IHC analysis, we confirmed that the NIRAPA signal corresponded with both CD68
283 and bilirubin (Fig. 4A-D), where the bilirubin was localized to an area more than 1 mm from the lumen,
284 and CD68 was detected within this region and a large surrounding area.

285

286 With the Seurat single cell sequencing analysis package³⁸, we found 3 distinct clusters in the stable
287 plaque. Through comparison between clusters and canonical cell markers commonly found in
288 atherosclerotic plaque⁴⁰⁻⁴², the identified clusters included a smooth muscle-like phenotype (actin and
289 collagen markers) surrounding the lumen, a myofibroblast cluster⁴¹ (*ACTA2*, *COL1A1*, *COL1A2*, *COL3A1*,
290 and *CNN2*) in the proximal plaque and macrophages (*CD163*, *CD68*, *CD14*, *HLA-DRB1*, and *APOE*) in
291 the distant plaque (Fig. 4E-F, Supplementary Table 1). Other groups have demonstrated that during
292 atherosclerosis, smooth muscle cells (SMCs) transdifferentiate into fibroblast-like or macrophage-like
293 cells⁴³ and can undergo clonal expansion⁴⁴. During transdifferentiation, SMCs begin to down-regulate
294 SMC specific phenotypes. Since our first cluster expressed both SMC and macrophage phenotypes, but
295 with a decreased expression, we annotated the first cluster as a SMC-derived intermediate. Comparing
296 the spatial transcriptomic results (Fig. 4E) with NIRAPA and NIRAF data (Fig. 4A-B), a segment of the
297 macrophage population overlapped with the intense NIRAF signal, and a population of macrophages
298 exhibited with a greatly reduced NIRAF signal. Maps of the spatial distribution of key markers (Fig. 4G)
299 further defined the spatial characteristics.

300

301 Since sequencing and NIRAF data indicated potential sub-macrophage populations, we computationally
302 isolated the macrophage cluster and further re-clustered with a higher resolution, following Seurat's
303 standard clustering protocol (Fig. 4H). Through high-resolution re-clustering, we discovered two distinct
304 macrophage subpopulations, which differentially expressed key gene markers (*CD74* and *SPP1*) (Fig.
305 4H). We then quantified the spatial correlation between the expression of various macrophage markers
306 (Fig. 4I), the correlation between inflammatory markers was greatest (0.8) between *HLA-DRA* and *CD74*
307 and was similarly large within the *SPP1* cluster. Based on select differentially-expressed genes of each
308 cluster, we found that macrophages with a greater imaging signal and higher *CD74* expression also co-
309 expressed MHC II (*HLA-DRA*) and *APOE*, while macrophages with higher *SPP1* expression co-

310 expressed *S100A10*, *MMP9*, *CTSB*, *IL1RN*, and *TREM1* (Fig. 4J). The cluster co-expressing
311 macrophage activation markers such as *CD74*, *APOE*, and *HLA-DRA* spatially overlapped with the
312 greater NIRAPA and NIRAF signals (Fig. 4K) with a significant correlation between the NIRAF signal
313 level and that of *CD74*, *CD163*, and *HLA-DRA* (Supplementary Fig. 3)⁴⁵. In contrast, the macrophage
314 cluster co-expressing *SPP1* and *CTSB* spatially overlapped with the reduced NIRAF signal (Fig. 4K,
315 Supplementary Fig. 3). *CTSB* is a cathepsin known to promote atherosclerotic inflammation and
316 vulnerability⁴¹ (Fig. 4K) and the *SPP1* and *CTSB* cluster is associated with foamy macrophages with an
317 M2-like phenotype⁴¹.

318
319 Since spatial transcriptomics identified inflammatory macrophage populations related to the NIRAF signal,
320 we probed the spatial protein distribution and the relationship between protein expression and the NIRAF
321 signal at the single-cell level in stable plaque (Fig. 5). We performed spatial proteomic imaging on slices
322 adjacent to the spatial transcriptomic studies and acquired the coincident NIRAF signal. Spatial
323 correlation between the NIRAF signal and MHCII (HLA-DR) and CD14 was 0.9 and 0.8, respectively (Fig.
324 5A-C), and HLA-DR and CD14 spatially correlate with one another at 0.9. As expected, the correlation of
325 the NIRAF signal with Collagen IV was low (0.2), and in this stable plaque, the correlation with CD163
326 was 0.2 (Fig. 5D). We segmented the cells based on the DAPI nuclear DNA stain and plotted cell
327 populations expressing each marker in a Venn diagram (Fig. 5E). The greatest marker overlap occurred
328 between CD14 and HLA-DR, with ~20% of the segmented cells displaying both markers.

329
330 To further characterize the source of the NIRAF and NIRAPA signal, we examined the CODEX images
331 with successively higher spatial resolution (Fig. 5F-G). As expected from Fig. 4A-D (bilirubin distribution),
332 we found that in some regions the NIRAF signal correlated with extracellular protein (regions of pink
333 fluorescence in the absence of a DAPI signal). Individual neovessels were identified deep within the
334 plaque, particularly in the NIRAPA region. The NIRAF/NIRAPA signal was frequently associated with
335 the presence of CD31⁺ angiogenic neovessels, which can facilitate red blood cell extravasation (Fig. 5F,
336 Collagen IV, CD31).

337
338 Signal overlap with the HLA-DR and CD14 markers was also detected and then probed at higher spatial
339 resolution in Fig. 5G. Individual cells were manually segmented and images were obtained with a set of
340 markers. The analysis confirmed that the signal was localized with the cytoplasm of CD68⁺ macrophages
341 with varied expression of HLA-DR, CD14, and CD163. This analysis also demonstrated that the markers
342 could be detected in these same regions without the presence of the NIRAF signal, suggesting that the
343 varied cellular contents and/or phagocytotic activity determine the strength of the NIRAF signal.

344
345 We next evaluated the spatial correspondence of the transcriptomic and proteomic signals
346 (Supplementary Fig. 4) in the structural features of the plaque. We found good agreement between the
347 key protein/gene pairs of interest; the α SMA/*ACTA2* signal was confirmed and correlated, the
348 CD31/*PECAM1* signal was correlated and the Collagen IV/*COL4A1* signal (which largely corresponds
349 with the blood vessels) was mapped. This is a particular advantage of combining these techniques, in
350 which spatial proteomics provides single-cell spatial resolution to detect features such as angiogenic
351 vessels, and spatial transcriptomics provides high-depth profiling of global gene expression.

352
353 In summary, the CODEX analysis of the stable plaque cross section confirmed the spatial RNA
354 sequencing results on a single-cell level. The NIRAF signal was spatially colocalized in some pixels
355 containing extracellular matrix without DAPI (spatially correlated with bilirubin) and individual
356 inflammatory cells expressing HLA-DR, CD14 and CD163.

357
358 **Spatial transcriptomic sequencing and proteomics highlights inflammatory macrophages lining**
359 **the lumen of vulnerable plaque**

360
361 We then evaluated the source of the signal in a vulnerable plaque (Fig. 6) where the corresponding CT
362 and NIRAPA images are summarized in Supplementary Fig. 5 and the associated videos. Here again,
363 the NIRAPA and NIRAF signals were similar and spatially localized within this vulnerable plaque. The

364 NIRAPA signal extended a smaller distance from the lumen, possibly due to the presence of proximal
365 calcification blocking light from entering the intact plaque. From Fig. 6A, the combination of the ultrasound
366 and NIRAPA signal suggested a very thin fibrous cap, and this was confirmed in Fig. 6B, as illustrated in
367 Fig. 6C. Both CD68 and bilirubin IHC were positive for the region of the active signal (Fig. 6D-E). Cluster
368 analysis of the spatial transcriptomic data again detected the presence of three clusters spanning
369 macrophages, myofibroblasts and an SMC intermediate cluster (Fig. 6F-G, Supplementary Table 2).
370 Here, the macrophage cluster was adjacent to the lumen (Fig. 6F). The macrophage cluster was further
371 analyzed to reveal foamy, *APOE*⁺ and inflammatory subclusters (Fig. 6H), with a thin layer of
372 inflammatory macrophages covering the lumen and correlated with the NIRAPA signal. This
373 inflammatory cluster highly expressed *CD74*, *HLA-DRA*, *CD14*, and *CD163* (Fig. 6I). Spatial mapping of
374 individual genes differentiated the macrophage clusters (Fig. 6J), with a region with enhanced *CD74*
375 expression outlined. CODEX imaging focused on this region revealed expression of angiogenic and
376 inflammatory macrophage markers (Fig. 6K).

377
378 The analysis of this vulnerable plaque was repeated in a second slice (Supplementary Fig. 6,
379 Supplementary Table 3) and confirmed the correspondence of the NIRAPA and NIRAF signals with a
380 macrophage (CD68) and bilirubin signal (Supplementary Fig. 6A-E), the existence of the inflammatory
381 macrophage mRNA near the lumen (Supplementary Fig. 6F-I). The co-expression of CD14 and HLA-
382 DR on ~20% of cells was observed (Supplementary Fig. 6J). Finally, in this vulnerable plaque, the
383 expression of the NIRAF signal within the cytoplasm of individual macrophages was confirmed on
384 CODEX imaging (Supplementary Fig. 6K). In summary, the NIRAPA technique was capable of detecting
385 regions of vulnerable plaque as a result of signals generated by extracellular protein and macrophages.

386
387

388 DISCUSSION

389

390 Standard imaging modalities for assessing carotid artery atherosclerosis include sonography, CT, MR
391 angiography, and digital subtraction angiography⁴⁶. Treatment decisions, including determining when to
392 offer surgical intervention, are primarily based on the degree of stenosis and the presence or absence of
393 clinical symptoms.⁴⁷ However, plaque size and the severity of stenosis are not necessarily correlated with
394 plaque vulnerability.³⁷ Many recent studies emphasize the importance of the plaque composition, which
395 has a significantly higher impact on plaque vulnerability than luminal stenosis and plaque size alone.⁴⁸⁻⁵¹
396 Unstable, or vulnerable, plaques are characterized by a thin fibrous cap, a large necrotic core,
397 neovascularization from vasa vasorum, and intraplaque hemorrhage^{15, 52-54}. CT is part of the current
398 guidelines for the assessment and management of carotid plaques. The degree of stenosis in
399 combination with clinical symptoms still guide the treatment decision. However, CT imaging alone cannot
400 assess plaque composition^{55, 56}, nor reliably differentiate fibrous tissue and intraplaque hemorrhage due
401 to the overlapping Hounsfield units of these components⁵⁷.

402

403 High-resolution MRI is used to accurately detect intraplaque hemorrhage, a marker of plaque vulnerability
404 in symptomatic and asymptomatic patients^{51, 58}. However, MRI is the most expensive imaging technique
405 and not broadly accessible, whereas photoacoustic imaging (PAI) in combination with ultrasound can be
406 integrated more broadly²¹. Further, mapping the fibrous cap thickness is challenging with MRI imaging.
407 PAI, utilizing our proposed auto-photoacoustic signal, would allow physicians to assess plaque
408 vulnerability quickly and affordably, thus potentially facilitating the identification of asymptomatic
409 individuals requiring treatment. This could lead to a significant reduction of adverse outcomes, as the
410 presence of intraplaque hemorrhage is an independent risk factor for stroke and coronary heart disease⁵¹.

411

412 For these reasons, new clinically-relevant imaging techniques such as PAI, in combination with novel
413 biomarkers, are needed to further improve plaque treatment regimens. In our study, we use
414 photoacoustic imaging to discriminate stable versus vulnerable plaque components based on naturally-
415 occurring near-infrared markers. Near-infrared autofluorescence (NIRAF) has been associated with lipids
416 and intraplaque hemorrhage. Macrophages, which are a marker of a vulnerable plaque, phagocytose
417 extravasated red blood cells, degrade heme to bilirubin, and are involved in the formation of insoluble

418 lipids or ceroids^{29, 31}. Here we show that the aforementioned endogenous near-infrared biomarkers,
419 especially in colocalization with macrophages, can be detected by PAI. Our results demonstrate that the
420 NIR-auto-photoacoustic (NIRAPA) signal in the 680-700 nm range can be combined with anatomic
421 ultrasound to distinguish stable from vulnerable plaque components. Especially in asymptomatic cases
422 where the need for surgery is still difficult to assess, PAI using the NIRAPA signal achieved significant
423 sensitivity of 87.5% and specificity of 100% (n=12). The sensitivity and specificity achieved with PAI
424 outperformed the classical symptoms/histology system. The higher sensitivity and specificity could also
425 be achieved due to the identification of asymptomatic vulnerable plaques, which represent the most
426 difficult to detect and potentially most clinically-relevant cases.

427
428 Of particular clinical relevance is the assessment of the fibrous cap thickness overlying the necrotic core,
429 which is a key source of inflammation and thrombogenicity in lesions at risk for erosion or frank rupture⁵⁹.
430 A fibrous cap measuring less than 65 μm is considered a vulnerable plaque³⁷. Photoacoustic images
431 overlaid on B-mode ultrasound images, with a resolution of 100 μm , allowed us to identify thick (>65 μm)
432 fibrous caps, based on the missing NIRAPA signal, and NIRAPA signal generating pathological tissue
433 components (macrophages, hemoglobin degradation products, necrotic material). The clinical
434 importance of the detected NIRAPA signal depends on its area and its localization with respect to the
435 plaque lumen. Some MRI-based studies have indicated that debris with a volume larger than 100 mm^3
436 can promote blood vessel occlusion and cause stroke⁶⁰.

437
438 Spatial transcriptomics is innately quantitative and was applied to cluster and assess the smooth muscle
439 and macrophage cell populations. With this technique, a layer of inflammatory macrophages and
440 angiogenic vasculature was detected on the luminal surface of the vulnerable plaque. The spatial RNA
441 sequencing results, in combination with spatial proteomics and IHC, confirmed spatial correlation of the
442 NIRAF signal and macrophages as well as hemoglobin degradation products^{29, 61}. Additionally, both
443 techniques revealed that inflammatory macrophages (*CD74*, *HLA-DRA*) were associated with a stronger
444 NIRAF signal than *SPP1*⁺ foamy macrophages.

445
446 By combining spatial transcriptomics and proteomics, we were also able to precisely determine the
447 source of the NIRAPA signal. First, CODEX imaging with the NIRAF signal overlay confirmed the
448 macrophage phenotypes associated with the NIRAPA signal on a single-cell level. Indeed, in a manner
449 similar to imaging cytometry, the localization of the NIRAPA signal within the macrophage cytoplasm was
450 confirmed. Second, the CODEX imaging mapped angiogenic vascular structures at a resolution not
451 feasible with Visium transcriptomics, where leaky, angiogenic vessels could be the source of the red
452 blood cells and their degradation products. While additional spatial transcriptomics technologies are
453 emerging, few will be able to provide single-cell resolution with a deep genetic profile, further emphasizing
454 the power of combinatorial -omics analyses. Third, with spatial proteomics, we confirmed that
455 extracellular protein was a partial source of the NIRAPA signal.

456
457 To compensate for the patient's differential light penetration properties, the PAI protocol should begin in
458 a vessel area without plaque. In this area, PAI can be calibrated and the laser intensity or wavelength
459 summation determined. Based on this PAI configuration, the operator should continue scanning the
460 plaque area. PA images within the NIR range of 680-700 nm overlaid on top of B-mode ultrasound images
461 then allow the assessment of the plaque wall. The size and location of the NIRAPA signal with respect
462 to the plaque lumen can be used to distinguish the respective plaque as stable versus vulnerable.
463 Differences between the NIRAPA signal and NIRAF are influenced by the plaque size and the resulting
464 illumination limitations of the whole plaque sample. This physical limitation of the current photoacoustic
465 devices may require the development of novel transducers, which circumvent the respective carotid
466 artery and therefore allow more holistic illumination and detection of plaque components.

467
468 Atherosclerosis is a dynamic process over time, which is characterized through different stages. Since
469 plaques are very common among aging adults and the majority consist of stable plaques which do not
470 impact the wellbeing of a patient, it is essential to identify and prioritize treatment of vulnerable plaques.
471 Carotid artery plaque management requires thorough surveillance due to the potential for devastating

472 morbidity from stroke. Depending on the plaque characteristics, different treatment strategies are
473 indicated, ranging from intensification of drug regimens to surgical interventions. To aid in predicting
474 which treatment strategy will be the most successful, the detection of this newly described naturally-
475 occurring near-infrared biomarker, which is associated with the presence of inflammatory markers such
476 as macrophages and the blood degradation product bilirubin, is crucial. Therefore, our results will lead to
477 more precision medicine and personally-tailored disease evaluation and treatment.

478
479
480 **Acknowledgements:** We dedicate this paper to our friend and colleague Dr. Sanjiv Sam Gambhir who
481 recruited Martin Schneider to Stanford University. This project was supported by the Stanford PHIND
482 Institute and NIH R01 CA250557 and NIHR01CA253316 through which we developed spatial sequencing
483 techniques. The sequencing data was generated with instrumentation purchased with NIH funds:
484 S10OD025212, 1S10OD021763, R35HL144475 and T32CA118681. This research was also supported
485 in part by a training grant from NIH Cellular and Molecular Training Grant (NIGMS, T32GM007276). The
486 Vevo LAZR-X equipment was provided for this study by Fujifilm VisualSonics. The assistance of
487 Alexander Trevino at Enable Medicine was greatly appreciated.

488
489 **Competing interests:** AM is an employee of EnableMedicine which develops CODEX-related
490 methodologies. All other authors declare no competing interest.

491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525

526 **References**

- 527 1. Libby, P. et al. Atherosclerosis. *Nat Rev Dis Primers* **5**, 56 (2019).
- 528 2. Organization, W.H. Cardiovascular diseases (CVDs) Fact Sheet. (2021).
- 529 3. Prevention, C.f.D.C.a. Mortality in the United States, 2020. (2021).
- 530 4. Hansson, G.K. & Hermansson, A. The immune system in atherosclerosis. *Nat Immunol* **12**, 204-
531 212 (2011).
- 532 5. Hansson, G.K. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* **352**,
533 1685-1695 (2005).
- 534 6. Prati, P. et al. Prevalence and determinants of carotid atherosclerosis in a general population.
535 *Stroke* **23**, 1705-1711 (1992).
- 536 7. Bergstrom, G. et al. Prevalence of Subclinical Coronary Artery Atherosclerosis in the General
537 Population. *Circulation* **144**, 916-929 (2021).
- 538 8. Tuzcu, E.M. et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and
539 young adults: evidence from intravascular ultrasound. *Circulation* **103**, 2705-2710 (2001).
- 540 9. Golledge, J., Greenhalgh, R.M. & Davies, A.H. The symptomatic carotid plaque. *Stroke* **31**, 774-
541 781 (2000).
- 542 10. Longstreth, W.T., Jr. et al. Asymptomatic internal carotid artery stenosis defined by ultrasound
543 and the risk of subsequent stroke in the elderly. The Cardiovascular Health Study. *Stroke* **29**,
544 2371-2376 (1998).
- 545 11. Vergallo, R. & Crea, F. Atherosclerotic Plaque Healing. *N Engl J Med* **383**, 846-857 (2020).
- 546 12. Kamtchum-Tatuene, J. et al. Prevalence of High-risk Plaques and Risk of Stroke in Patients
547 With Asymptomatic Carotid Stenosis: A Meta-analysis. *JAMA Neurol* **77**, 1524-1535 (2020).
- 548 13. Li, J. et al. Multimodality Intravascular Imaging of High-Risk Coronary Plaque. *JACC Cardiovasc*
549 *Imaging* **15**, 145-159 (2022).
- 550 14. Narula, J. et al. Histopathologic characteristics of atherosclerotic coronary disease and
551 implications of the findings for the invasive and noninvasive detection of vulnerable plaques. *J*
552 *Am Coll Cardiol* **61**, 1041-1051 (2013).
- 553 15. Burke, A.P. et al. Coronary risk factors and plaque morphology in men with coronary disease
554 who died suddenly. *N Engl J Med* **336**, 1276-1282 (1997).
- 555 16. Davies, M.J. & Thomas, A.C. Plaque fissuring--the cause of acute myocardial infarction, sudden
556 ischaemic death, and crescendo angina. *Br Heart J* **53**, 363-373 (1985).
- 557 17. Howard, D.P. et al. Symptomatic carotid atherosclerotic disease: correlations between plaque
558 composition and ipsilateral stroke risk. *Stroke* **46**, 182-189 (2015).
- 559 18. JM, U.K.-I., Young, V. & Gillard, J.H. Carotid-artery imaging in the diagnosis and management
560 of patients at risk of stroke. *Lancet Neurol* **8**, 569-580 (2009).
- 561 19. Zhu, G. et al. Carotid plaque imaging and the risk of atherosclerotic cardiovascular disease.
562 *Cardiovasc Diagn Ther* **10**, 1048-1067 (2020).
- 563 20. Ivankovic, I., Mercep, E., Schmedt, C.G., Dean-Ben, X.L. & Razansky, D. Real-time Volumetric
564 Assessment of the Human Carotid Artery: Handheld Multispectral Optoacoustic Tomography.
565 *Radiology* **291**, 45-50 (2019).
- 566 21. Steinberg, I. et al. Photoacoustic clinical imaging. *Photoacoustics* **14**, 77-98 (2019).
- 567 22. Weber, J., Beard, P.C. & Bohndiek, S.E. Contrast agents for molecular photoacoustic imaging.
568 *Nat Methods* **13**, 639-650 (2016).
- 569 23. Zackrisson, S., van de Ven, S. & Gambhir, S.S. Light in and sound out: emerging translational
570 strategies for photoacoustic imaging. *Cancer Res* **74**, 979-1004 (2014).
- 571 24. Kruizinga, P. et al. Photoacoustic imaging of carotid artery atherosclerosis. *J Biomed Opt* **19**,
572 110504 (2014).
- 573 25. Allen, T.J., Hall, A., Dhillon, A.P., Owen, J.S. & Beard, P.C. Spectroscopic photoacoustic
574 imaging of lipid-rich plaques in the human aorta in the 740 to 1400 nm wavelength range. *J*
575 *Biomed Opt* **17**, 061209 (2012).
- 576 26. Karlas, A. et al. Multispectral optoacoustic tomography of lipid and hemoglobin contrast in
577 human carotid atherosclerosis. *Photoacoustics* **23**, 100283 (2021).
- 578 27. Arabul, M.U. et al. Toward the detection of intraplaque hemorrhage in carotid artery lesions
579 using photoacoustic imaging. *J Biomed Opt* **22**, 41010 (2017).

- 580 28. Muller, J.W. et al. Towards in vivo photoacoustic imaging of vulnerable plaques in the carotid
581 artery. *Biomed Opt Express* **12**, 4207-4218 (2021).
- 582 29. Htun, N.M. et al. Near-infrared autofluorescence induced by intraplaque hemorrhage and heme
583 degradation as marker for high-risk atherosclerotic plaques. *Nat Commun* **8**, 75 (2017).
- 584 30. Wang, H. et al. Ex vivo catheter-based imaging of coronary atherosclerosis using multimodality
585 OCT and NIRAF excited at 633 nm. *Biomed Opt Express* **6**, 1363-1375 (2015).
- 586 31. Albaghdadi, M.S. et al. Near-Infrared Autofluorescence in Atherosclerosis Associates With
587 Ceroid and Is Generated by Oxidized Lipid-Induced Oxidative Stress. *Arterioscler Thromb Vasc*
588 *Biol* **41**, e385-e398 (2021).
- 589 32. Chen, Z., Dean-Ben, X.L., Gottschalk, S. & Razansky, D. Performance of optoacoustic and
590 fluorescence imaging in detecting deep-seated fluorescent agents. *Biomed Opt Express* **9**,
591 2229-2239 (2018).
- 592 33. Black, S. et al. CODEX multiplexed tissue imaging with DNA-conjugated antibodies. *Nat Protoc*
593 **16**, 3802-3835 (2021).
- 594 34. Fernandez, D.M. & Giannarelli, C. Immune cell profiling in atherosclerosis: role in research and
595 precision medicine. *Nat Rev Cardiol* **19**, 43-58 (2022).
- 596 35. Paik, D.T., Cho, S., Tian, L., Chang, H.Y. & Wu, J.C. Single-cell RNA sequencing in
597 cardiovascular development, disease and medicine. *Nat Rev Cardiol* **17**, 457-473 (2020).
- 598 36. Stahl, P.L. et al. Visualization and analysis of gene expression in tissue sections by spatial
599 transcriptomics. *Science* **353**, 78-82 (2016).
- 600 37. Virmani, R., Burke, A.P., Farb, A. & Kolodgie, F.D. Pathology of the vulnerable plaque. *J Am*
601 *Coll Cardiol* **47**, C13-18 (2006).
- 602 38. Hao, Y. et al. Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573-3587 e3529
603 (2021).
- 604 39. Virmani, R., Burke, A.P., Farb, A. & Kolodgie, F.D. Pathology of the Vulnerable Plaque. *Journal*
605 *of the American College of Cardiology* **47**, C13-C18 (2006).
- 606 40. Winkels, H. et al. Atlas of the Immune Cell Repertoire in Mouse Atherosclerosis Defined by
607 Single-Cell RNA-Sequencing and Mass Cytometry. *Circ Res* **122**, 1675-1688 (2018).
- 608 41. Willemsen, L. & de Winther, M.P. Macrophage subsets in atherosclerosis as defined by single-
609 cell technologies. *J Pathol* **250**, 705-714 (2020).
- 610 42. Wirka, R.C. et al. Atheroprotective roles of smooth muscle cell phenotypic modulation and the
611 TCF21 disease gene as revealed by single-cell analysis. *Nat Med* **25**, 1280-1289 (2019).
- 612 43. Pan, H. et al. Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell
613 Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse and
614 Human. *Circulation* **142**, 2060-2075 (2020).
- 615 44. Wang, Y. et al. Clonally expanding smooth muscle cells promote atherosclerosis by escaping
616 efferocytosis and activating the complement cascade. *Proceedings of the National Academy of*
617 *Sciences* **117**, 15818-15826 (2020).
- 618 45. Fernandez, D.M. et al. Single-cell immune landscape of human atherosclerotic plaques. *Nat*
619 *Med* **25**, 1576-1588 (2019).
- 620 46. Saba, L. et al. Carotid Artery Wall Imaging: Perspective and Guidelines from the ASNR Vessel
621 Wall Imaging Study Group and Expert Consensus Recommendations of the American Society
622 of Neuroradiology. *AJNR Am J Neuroradiol* **39**, E9-E31 (2018).
- 623 47. Saba, L. et al. Roadmap Consensus on Carotid Artery Plaque Imaging and Impact on Therapy
624 Strategies and Guidelines: An International, Multispecialty, Expert Review and Position
625 Statement. *AJNR Am J Neuroradiol* **42**, 1566-1575 (2021).
- 626 48. Chai, J.T. et al. Quantification of Lipid-Rich Core in Carotid Atherosclerosis Using Magnetic
627 Resonance T(2) Mapping: Relation to Clinical Presentation. *JACC Cardiovasc Imaging* **10**, 747-
628 756 (2017).
- 629 49. Bos, D. et al. Advances in Multimodality Carotid Plaque Imaging: AJR Expert Panel Narrative
630 Review. *AJR Am J Roentgenol* **217**, 16-26 (2021).
- 631 50. Daghem, M., Bing, R., Fayad, Z.A. & Dweck, M.R. Noninvasive Imaging to Assess
632 Atherosclerotic Plaque Composition and Disease Activity: Coronary and Carotid Applications.
633 *JACC Cardiovasc Imaging* **13**, 1055-1068 (2020).

- 634 51. Bos, D. et al. Atherosclerotic Carotid Plaque Composition and Incident Stroke and Coronary
635 Events. *J Am Coll Cardiol* **77**, 1426-1435 (2021).
- 636 52. Naghavi, M. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and
637 risk assessment strategies: Part II. *Circulation* **108**, 1772-1778 (2003).
- 638 53. Carr, S., Farb, A., Pearce, W.H., Virmani, R. & Yao, J.S. Atherosclerotic plaque rupture in
639 symptomatic carotid artery stenosis. *J Vasc Surg* **23**, 755-765; discussion 765-756 (1996).
- 640 54. Falk, E., Nakano, M., Bentzon, J.F., Finn, A.V. & Virmani, R. Update on acute coronary
641 syndromes: the pathologists' view. *Eur Heart J* **34**, 719-728 (2013).
- 642 55. Millon, A. et al. High-resolution magnetic resonance imaging of carotid atherosclerosis identifies
643 vulnerable carotid plaques. *J Vasc Surg* **57**, 1046-1051 e1042 (2013).
- 644 56. Grimm, J.M. et al. Comparison of symptomatic and asymptomatic atherosclerotic carotid
645 plaques using parallel imaging and 3 T black-blood in vivo CMR. *J Cardiovasc Magn Reson* **15**,
646 44 (2013).
- 647 57. Saba, L. et al. Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and
648 their potential clinical implications. *Lancet Neurol* **18**, 559-572 (2019).
- 649 58. Gupta, A. et al. Carotid plaque MRI and stroke risk: a systematic review and meta-analysis.
650 *Stroke* **44**, 3071-3077 (2013).
- 651 59. Kojima, Y., Weissman, I.L. & Leeper, N.J. The Role of Efferocytosis in Atherosclerosis.
652 *Circulation* **135**, 476-489 (2017).
- 653 60. Takaya, N. et al. Presence of intraplaque hemorrhage stimulates progression of carotid
654 atherosclerotic plaques: a high-resolution magnetic resonance imaging study. *Circulation* **111**,
655 2768-2775 (2005).
- 656 61. Chinetti-Gbaguidi, G., Colin, S. & Staels, B. Macrophage subsets in atherosclerosis. *Nat Rev*
657 *Cardiol* **12**, 10-17 (2015).

658

659 **Data availability**

660 The main data supporting the findings of this study are available within the paper and its Supplementary
661 Information. The raw and analyzed datasets will be made available through an appropriate data server
662 upon acceptance of the paper.

663

664

665 **Author contributions:** M.K.S., J.W., N.J.L., J.J.H., K.W.F conceived and designed the experiments.
666 M.K.S., J.W., D.W., J.C., S.S.A., C.F.B., T.A., G.K.S, S.J.S, A.M., performed the experiments. M.K.S.,
667 J.W., A.K., D.S., S.S.A., A.B., S.R.L, M.G.L, N.J.L, J.J.H., K.W.F. analyzed the results. M.K.S., J.W., A.K.,
668 K.W.F. wrote the manuscript. K.W.F supervised the entire project. All authors discussed the results and
669 commented on the manuscript.

670

671

672

673

674


675

676

677

678

679




680

681 **Graphical Abstract**

682


683

684



685 **Figure 1. Photoacoustic imaging of the near-infrared auto-photoacoustic (NIRAPA) biomarker in human**
686 **carotid plaque.** A) Schematic of human carotid endarterectomy (CEA) sample. B) Human carotid plaque under
687 white light. C-E) Longitudinal anatomic C) NIRAPA, D) computed tomography (CT) and E) color flow ultrasound
688 (US) images of human carotid plaque. The dashed lines on the longitudinal image in (C) represent the imaging
689 locations of the axial images in columns i, ii and iii in (F). F) Comparison of the NIRAPA signal (680-700nm) with
690 NIRAF and Masson's trichrome, CD68, bilirubin, H&E and picrosirius red staining for the three tissue section
691 locations, i, ii and iii, indicated in Fig. 1C. Scale bar, bottom right, applies all panels in F.

692



693


694 **Figure 2. Measurements of fibrous cap thickness and plaque volume by histology and imaging establish**
 695 **sensitivity and specificity of the imaging technique.** A) Measurements and correlation of fibrous cap thickness
 696 on NIRAPA (680-700 nm)-US images and picosirius red (PSR) histopathology with $r^2=0.99$. B) Measurements and
 697 correlation of the vulnerable plaque volume (red outline) on NIRAPA (680-700 nm)-US images and picosirius red
 698 histopathology with $r^2=0.86$. C) Photoacoustic (PA) signal intensity of NIRAPA (680-700 nm) averaged in vulnerable
 699 (red outline) and stable (green outline) plaque areas. Picosirius red histopathology shows correlating areas.
 700 $p<0.0001$. D) Representative PA NIRAPA-US images of asymptomatic stable, asymptomatic vulnerable (unstable)
 701 and symptomatic vulnerable plaque cases. Correlating Masson's trichrome stains. E) Summary of diagnostic
 702 accuracy of fibrous cap thickness as measured by photoacoustic imaging compared with histological classification.
 703 Vulnerable plaque defined as fibrous cap not existing or $<65 \mu\text{m}$. PPV: positive predictive value, NPV: negative
 704 predictive value, L: lumen, ****, $p<0.0001$. n=25 patients.

706

707

708

709



710
711 **Figure 3. NIRAF signal correlates with CD68 and bilirubin.** A) Overview of representative H&E, Masson's
712 trichrome and picrosirius red images used to localize the image features. CD68, bilirubin and αSMA images
713 provided for reference. If NIRAF was detected, results were used to calculate the Pearson's Coefficient (termed
714 NIRAF True Positive, pink highlighted column). L: Lumen, F: Fibrous Cap, Necrotic: If NIRAF was not detected, the
715 percentage pixel area was calculated (termed NIRAF True Negative, gray highlighted column). B) Pearson's
716 Coefficient results based on the colocalization of CD68, bilirubin and αSMA with respect to the NIRAF image. C)
717 Difference in the analyzed pixel area of CD68, bilirubin or αSMA, when NIRAF was not detected. ****, $p < 0.0001$,
718 $n = 25$ patients.
719

720

721

722

723

724

725

726

727

728

729


730

731

732

733

734



735
736
737
738
739
740
741
742
743
744
745

Figure 4. Spatial transcriptomic analysis of stable plaque specimen identifies specific macrophage populations that spatially correlate with the NIRAF and NIRAPA signals. A-B) NIRAPA (A) and NIRAF (B) images of a carotid plaque cross section. Annotations indicate strong (white) and weaker (yellow) NIRAF signal. C) Cartoon summarizing the stable plaque features and the location of the NIRAPA signal. D) Histological sections of the carotid endarterectomy (CEA) plaque specimen stained with CD68 and bilirubin. E) Overlay and Uniform Manifold Approximation and Projection (UMAP) cluster projection of spatial transcriptomics on carotid plaque H&E. Based on their gene expression, clusters have been assigned to macrophage, myofibroblast and smooth muscle cell (SMC) intermediate cell types. F) Overall heatmap of the general immunological signatures that differentiate the macrophage, myofibroblast and SMC intermediate clusters. G) Key genes that differentiate macrophage, myofibroblast, and SMC intermediate populations and their spatial intensity on the CEA specimen. H) Spatial

746 deconvolution and UMAP cluster projection of the macrophage cluster in *CD74*⁺ and *SPP1*⁺ regions and the spatial
747 location on the H&E-stained plaque cross section. UMAP projection of macrophage high resolution subtype
748 clustering shows *CD74*⁺ and *SPP1*⁺ populations. I) Pearson's correlation between genes within the macrophage
749 clusters. J) Heatmap of macrophage-specific gene signatures that differentiate the *CD74*⁺ and *SPP1*⁺ macrophage
750 subpopulations. K) Key genes differentiating inflammatory (*CD74*⁺) and foamy (*SPP1*⁺) macrophages and their
751 spatial location on the CEA specimen. p value cutoff is 0.005. L: Lumen. Log₂FC cutoff is 2.
752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780





Figure 5. Spatial proteomic analysis of resolved single cells and correlation with overlaid NIRAF signal in a stable plaque. A) H&E cross section overview with black box showing CODEX region. B) CODEX images showing signal intensities of CD68, CD14, HLA-DR and CD163 on the same tissue section. C) CODEX image of NIRAF signal intensity on the same tissue section with the high-NIRAF signal region highlighted and the boxed region studied further in F. D) Pearson's correlation between the NIRAF signal, genes within the macrophage clusters and Collagen IV. E) Venn diagram of the expression of HLA-DR, CD163 and CD14 based on segmented cells from CODEX images. F) ROI images of CODEX showing DAPI, NIRAF, Collagen IV, HLA-DR, CD14, CD163 and CD31. G) Representative manually-segmented individual cell fluorescence examples from CODEX.

781
782
783
784
785
786
787
788
789
790



791
792
793
794
795
796
797
798
799

Figure 6. Spatial transcriptomic and proteomic analysis of vulnerable plaque delineates spatially-dependent macrophage populations. A-B NIRAPA (A) and NIRAF (B) images of a carotid plaque cross section. C) Cartoon summarizing the vulnerable plaque features and the location of the NIRAPA signal. D-E) Histological sections of the carotid endarterectomy (CEA) plaque specimen stained with CD68 (D) and bilirubin (E). F) Overlay and Uniform Manifold Approximation and Projection (UMAP) cluster projection of spatial transcriptomics on carotid plaque H&E. Based on their gene expression, clusters have been assigned to macrophage, myofibroblast and smooth muscle cell (SMC) intermediate cell types. G) Overall heatmap of general immunological signatures that differentiate the macrophage, myofibroblast and SMC intermediate clusters. H) Spatial deconvolution and UMAP

800 cluster projection of the macrophage cluster in inflammatory *CD74*⁺, foamy *SPP1*⁺, and *APOE*⁺ regions and the
801 spatial location on the H&E-stained plaque cross section. UMAP projection of macrophage high resolution subtype
802 clustering shows *CD74*⁺, *SPP1*⁺, and *APOE*⁺ populations. I) Heatmap of macrophage-specific gene signatures that
803 differentiate the *CD74*⁺, *SPP1*⁺, and *APOE*⁺ macrophage subpopulations. J) Key genes differentiating inflammatory
804 (*CD74*⁺) and foamy (*SPP1*⁺) macrophages and their spatial location on the CEA specimen. A region with enhanced
805 *CD74* expression is outlined in a black box overlay and investigated further in (K). K) CODEX imaging of DAPI
806 nuclear DNA stain, NIRAF, CD31, CD14, and HLA-DR in two areas of the vulnerable plaque region showing
807 enhanced *CD74* expression. P value cutoff is 0.005. Log₂FC cutoff is 2.
808